MindMaze Therapeutics Holding (CHIX:MMTXZ) Tax Expense: CHF Mil (TTM As of Dec. 2025)


CHIX:MMTXZ MindMaze Therapeutics Holding SA CHIX:MMTXZ
15 GF Score
Price CHF0.21
! 2 Warning Signs
View Full Analysis

What is MindMaze Therapeutics Holding Tax Expense?

MindMaze Therapeutics Holding CHIX:MMTXZ +4.74% 15 Tax Expense is CHF Mil as of Dec. 2025. GuruFocus rates CHIX:MMTXZ with a GF Score™ of 15/100. The stock has 2 warning signs investors should review.

MindMaze Therapeutics Holding's tax expense for the six months ended in Dec. 2025 was CHF0.00 Mil.


MindMaze Therapeutics Holding  (CHIX:MMTXz) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


MindMaze Therapeutics Holding Tax Expense Related Terms


MindMaze Therapeutics Holding Tax Expense Historical Data

* Premium members only.

The historical data trend for MindMaze Therapeutics Holding's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MindMaze Therapeutics Holding Tax Expense Chart

MindMaze Therapeutics Holding Annual Data
Trend Dec24 Dec25
Tax Expense
0.00 0.00

MindMaze Therapeutics Holding Semi-Annual Data
Dec24 Dec25
Tax Expense 0.00 0.00
CHIX:MMTXZ
15GF Score
MindMaze Therapeutics Holding SA CHIX:MMTXZ
Tax Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MindMaze Therapeutics Holding Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Frequently Asked Questions Learn more about Tax Expense →
What does a Tax Expense of CHF Mil mean?
MindMaze Therapeutics Holding (CHIX:MMTXZ) has a Tax Expense of CHF Mil as of Dec. 2025. Tax expense is the amount of tax the company pays in an accounting period. View historical data on MindMaze Therapeutics Holding and its competitors.
Is MindMaze Therapeutics Holding's Tax Expense too high?
MindMaze Therapeutics Holding's current Tax Expense is CHF Mil. Overall, MindMaze Therapeutics Holding has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does MindMaze Therapeutics Holding's Tax Expense compare to VRTX and REGN?
MindMaze Therapeutics Holding's Tax Expense of CHF Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Expense for a Biotechnology company?
A good Tax Expense depends on the Biotechnology industry context. However, Tax Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Expense mean?
A high Tax Expense can signal that a stock is expensive relative to its fundamentals. Tax expense is the amount of tax the company pays in an accounting period. View historical data on MindMaze Therapeutics Holding and its competitors. MindMaze Therapeutics Holding's current Tax Expense is CHF Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindMaze Therapeutics Holding stock overvalued right now?
MindMaze Therapeutics Holding (CHIX:MMTXZ) has a current Tax Expense of CHF Mil. The current Tax Expense is CHF Mil. MindMaze Therapeutics Holding's overall GF Score™ is 15/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Expense calculated?
Tax Expense is calculated from a company's financial statements. For MindMaze Therapeutics Holding (CHIX:MMTXZ), the current Tax Expense is CHF Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MindMaze Therapeutics Holding Business Description

Other Exchanges RLFTY:USAMMTX:Switzerland
Address Avenue de Secheron 15, Geneva, CHE, 1202
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
15GF Score

Get the complete analysis for CHIX:MMTXZ

Tax Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF0.21
Price